While AS has been extensively studied for its role in therapeutic resistance, the contribution of splicing factors (SFs), such as SRSF1, to BC progression and drug resistance is gaining increasing recognition and deserves further investigation. The gene discussed is SRSF1; the disease is breast cancer.